Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).
2026-07-03

Keywords:
Related information
Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).
2026-07-03
According to the drug approval document delivery information released by the NMPA, sildenafil citrate orally disintegrating tablets manufactured by Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. have been approved for marketing as a Class 4 generic drug under the new chemical drug registration classification, and are deemed to have passed the consistency evaluation.
2026-06-29
A Strong Start to the New Year – Kangchuanji Achieves Multiple Approvals
The new year begins with a wave of good news. Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. has made an excellent start, backed by professional expertise. According to NMPA drug approval information, the following products have been approved for marketing or have passed consistency evaluation: Famotidine Injection (2ml:20mg), Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (2.5/1000mg and 5/1000mg), Isosorbide Dinitrate Tablets (5mg), Vitamin B6 Injection (100mg/ml), Cefdinir Granules (50mg/0.5g), and Ambroxol and Clenbuterol Oral Solution (1ml: ambroxol hydrochloride 1.5mg and clenbuterol hydrochloride 1μg). Among these, Isosorbide Dinitrate Tablets are the first in China to pass consistency evaluation. As a partner, Kangchuanji provided solid pharmaceutical R&D services, successfully supporting these drugs through the review and approval process.
2026-03-23